WO2020138517A1 - PHARMACOLOGICAL COMPOSITION COMPRISING ANTI-TNFα ANTIBODY - Google Patents

PHARMACOLOGICAL COMPOSITION COMPRISING ANTI-TNFα ANTIBODY Download PDF

Info

Publication number
WO2020138517A1
WO2020138517A1 PCT/KR2018/016606 KR2018016606W WO2020138517A1 WO 2020138517 A1 WO2020138517 A1 WO 2020138517A1 KR 2018016606 W KR2018016606 W KR 2018016606W WO 2020138517 A1 WO2020138517 A1 WO 2020138517A1
Authority
WO
WIPO (PCT)
Prior art keywords
tnfα antibody
pharmacological composition
composition
phase
liquid
Prior art date
Application number
PCT/KR2018/016606
Other languages
French (fr)
Korean (ko)
Inventor
이재민
손유나
강정훈
김미경
김동규
김인애
김용국
박동국
윤지훈
황수정
박수진
Original Assignee
삼성바이오에피스 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 삼성바이오에피스 주식회사 filed Critical 삼성바이오에피스 주식회사
Priority to PCT/KR2018/016606 priority Critical patent/WO2020138517A1/en
Priority to TW108112031A priority patent/TW202023610A/en
Publication of WO2020138517A1 publication Critical patent/WO2020138517A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Abstract

The present invention provides a stable liquid-phase aqueous composition comprising an anti-TNFα antibody and, more particularly, to a liquid-phase pharmacological composition.
PCT/KR2018/016606 2018-12-24 2018-12-24 PHARMACOLOGICAL COMPOSITION COMPRISING ANTI-TNFα ANTIBODY WO2020138517A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/KR2018/016606 WO2020138517A1 (en) 2018-12-24 2018-12-24 PHARMACOLOGICAL COMPOSITION COMPRISING ANTI-TNFα ANTIBODY
TW108112031A TW202023610A (en) 2018-12-24 2019-04-03 Pharmaceutical composition comprising anti-tnf alpha antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2018/016606 WO2020138517A1 (en) 2018-12-24 2018-12-24 PHARMACOLOGICAL COMPOSITION COMPRISING ANTI-TNFα ANTIBODY

Publications (1)

Publication Number Publication Date
WO2020138517A1 true WO2020138517A1 (en) 2020-07-02

Family

ID=71126038

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/016606 WO2020138517A1 (en) 2018-12-24 2018-12-24 PHARMACOLOGICAL COMPOSITION COMPRISING ANTI-TNFα ANTIBODY

Country Status (1)

Country Link
WO (1) WO2020138517A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140092236A (en) * 2002-08-16 2014-07-23 애브비 바이오테크놀로지 리미티드 PHARMACEUTICAL ANTI-TNF-α ANTIBODY FORMULATION
US20150150982A1 (en) * 2012-06-12 2015-06-04 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
KR20150063305A (en) * 2013-11-29 2015-06-09 한화케미칼 주식회사 A liquid formulation of a fusion protein comprising TNFR and Fc region
KR20170005864A (en) * 2014-05-23 2017-01-16 아레스 트레이딩 에스.아. Liquid pharmaceutical composition
JP2017516847A (en) * 2014-05-23 2017-06-22 アレス トレーディング ソシエテ アノニム Liquid pharmaceutical composition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140092236A (en) * 2002-08-16 2014-07-23 애브비 바이오테크놀로지 리미티드 PHARMACEUTICAL ANTI-TNF-α ANTIBODY FORMULATION
US20150150982A1 (en) * 2012-06-12 2015-06-04 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
KR20150063305A (en) * 2013-11-29 2015-06-09 한화케미칼 주식회사 A liquid formulation of a fusion protein comprising TNFR and Fc region
KR20170005864A (en) * 2014-05-23 2017-01-16 아레스 트레이딩 에스.아. Liquid pharmaceutical composition
JP2017516847A (en) * 2014-05-23 2017-06-22 アレス トレーディング ソシエテ アノニム Liquid pharmaceutical composition

Similar Documents

Publication Publication Date Title
EP3765522A4 (en) Anti-claudin 18.2 antibodies
EP3808376A4 (en) Antibody targeting cldn18.2, bispecific antibody, adc, and car, and applications thereof
EP3794037A4 (en) Anti-claudin 18.2 antibodies and uses thereof
EP3762031A4 (en) Anti-claudin 18.2 antibodies and uses thereof
PH12020500398A1 (en) Antibody-pyrrolobenzodiazepine derivative conjugate
ZA202102549B (en) Substituted tolyl as fungicides
EP4257613A3 (en) Bispecific checkpoint inhibitor antibodies
WO2018109174A3 (en) Il-11 antibodies
WO2018109170A3 (en) Il-11ra antibodies
EP3873468A4 (en) 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors
CA3091731A1 (en) Endophyte compositions and methods for improvement of plant traits
CA3091744A1 (en) Endophyte compositions and methods for improvement of plant traits
AU2018258581A8 (en) RAF-degrading conjugate compounds
WO2019020602A3 (en) Phosphor and a composition
EP3872093A4 (en) Anti-cldn18.2 antibody and uses thereof
EP4017883A4 (en) Novel anti-cldn18.2 antibodies
MY189618A (en) Antibody specifically binding to pd-1 and functional fragment thereof
PH12019500551A1 (en) Antibody specifically binding to il-17a and functional fragment thereof
MX2018003297A (en) Precision applicator.
EP3883970A4 (en) An anti-b7-h3 antibody
EP3692072A4 (en) Anti-hla-dq2.5 antibody
MX2021007274A (en) Bifunctional anti-pd-1/sirpa molecule.
WO2018101663A3 (en) Composition for biotissue clearing and biotissue clearing method using same
MX2019010367A (en) Aqueous anti-pd-l1 antibody formulation.
EP3947466A4 (en) Anti-hla-dq2.5 antibody

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18944747

Country of ref document: EP

Kind code of ref document: A1

WA Withdrawal of international application
NENP Non-entry into the national phase

Ref country code: DE